Serum PCSK9 and MYLIP/IDOL Levels in Familial Hypercholesterolemia: Relationship with Lipid Profile

Background: Familial Hypercholesterolemia (FH), which is defined as a genetic disorder that causes a person to have high levels of LDL-C for their entire life, and therefore increases the risk of heart disease. Both PCSK9 and MYLIP/IDOL are proteins involved in regulating the amount of LDL receptors present on cell surfaces, but use different mechanisms. Objective: To compare the levels of serum PCSK9 and MYLIP/IDOL along with other lipid-profile parameters between healthy individuals, untreated FH patients, and treated FH patients. Methods: A cross-sectional study comparing three groups of individuals with different types of hypercholesterolemia was conducted among 90 subjects from Baghdad, Iraq (age 20-50 years): 30 normal control group members; 30 untreated familial hypercholesterolemia (FH) patients; and 30 treated FH patients. The serum PCSK9 and MYLIP/IDOL levels were determined via sandwich ELISA, while the concentrations of TC, TG, HDL-C, and LDL-C were evaluated through the use of a Roche Cobas Integra 400 analyzer. Results: There were differences among groups in all parameters measured (P<0.0001). The untreated FH group exhibited higher TC, TG, LDL-C, PCSK9, and MYLIP/IDOL than the control group; however, the untreated FH group also exhibited lower HDL-C than the control group. When compared to the untreated FH group, the treated FH group exhibited lower TC, LDL-C, and MYLIP/IDOL; conversely, the treated FH group also exhibited higher HDL-C and PCSK9 than the untreated FH group. After multiplicity adjustment, there were no differences between groups in terms of TG. The untreated FH group exhibited a positive correlation between MYLIP/IDOL and TC (r=0.607; adjusted P=0.0034). ROC analyses demonstrated that the highest area under curves (AUCs) were observed for LDL-C (1.000), TC (0.983), MYLIP/IDOL (0.982), and PCSK9 (0.921). Conclusion: There were significant lipid alterations in FH patients, which were accompanied by differences in PCSK9 and MYLIP/IDOL levels. Although treated FH patients had higher PCSK9 levels than untreated FH patients, their MYLIP/IDOL levels were lower. This may reflect different regulatory mechanisms for the LDL receptor pathway after treatment.

Authors

Institutions

Publication Details

Journal
NIU Journal of Health Sciences
Published
2026-11-16
DOI
https://doi.org/10.58709/niujhs.v12i3.2776
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Serum PCSK9 and MYLIP/IDOL Levels in Familial Hypercholesterolemia: Relationship with Lipid Profile

Ghufran Saad Nsaif
1 links
NIU Journal of Health Sciences
Lipoproteins and Cardiovascular Health
article

Serum PCSK9 and MYLIP/IDOL Levels in Familial Hypercholesterolemia: Relationship with Lipid Profile

Ghufran Saad Nsaif
article en

Abstract

Background: Familial Hypercholesterolemia (FH), which is defined as a genetic disorder that causes a person to have high levels of LDL-C for their entire life, and therefore increases the risk of heart disease. Both PCSK9 and MYLIP/IDOL are proteins involved in regulating the amount of LDL receptors present on cell surfaces, but use different mechanisms. Objective: To compare the levels of serum PCSK9 and MYLIP/IDOL along with other lipid-profile parameters between healthy individuals, untreated FH patients, and treated FH patients. Methods: A cross-sectional study comparing three groups of individuals with different types of hypercholesterolemia was conducted among 90 subjects from Baghdad, Iraq (age 20-50 years): 30 normal control group members; 30 untreated familial hypercholesterolemia (FH) patients; and 30 treated FH patients. The serum PCSK9 and MYLIP/IDOL levels were determined via sandwich ELISA, while the concentrations of TC, TG, HDL-C, and LDL-C were evaluated through the use of a Roche Cobas Integra 400 analyzer. Results: There were differences among groups in all parameters measured (P<0.0001). The untreated FH group exhibited higher TC, TG, LDL-C, PCSK9, and MYLIP/IDOL than the control group; however, the untreated FH group also exhibited lower HDL-C than the control group. When compared to the untreated FH group, the treated FH group exhibited lower TC, LDL-C, and MYLIP/IDOL; conversely, the treated FH group also exhibited higher HDL-C and PCSK9 than the untreated FH group. After multiplicity adjustment, there were no differences between groups in terms of TG. The untreated FH group exhibited a positive correlation between MYLIP/IDOL and TC (r=0.607; adjusted P=0.0034). ROC analyses demonstrated that the highest area under curves (AUCs) were observed for LDL-C (1.000), TC (0.983), MYLIP/IDOL (0.982), and PCSK9 (0.921). Conclusion: There were significant lipid alterations in FH patients, which were accompanied by differences in PCSK9 and MYLIP/IDOL levels. Although treated FH patients had higher PCSK9 levels than untreated FH patients, their MYLIP/IDOL levels were lower. This may reflect different regulatory mechanisms for the LDL receptor pathway after treatment.

NIU Journal of Health SciencesVol. 12(3)
University of Baghdad (IQ)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon